hVIVO (LON:HVO) Insider Brendan Buckley Sells 2,017,000 Shares of Stock

hVIVO plc (LON:HVO) insider Brendan Buckley sold 2,017,000 shares of the firm’s stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of GBX 9, for a total transaction of £181,530.

hVIVO Trading Up 2.0%

hVIVO stock opened at GBX 7.75 on Friday. The company has a 50 day moving average price of GBX 7.94 and a 200 day moving average price of GBX 6.88. hVIVO plc has a 52 week low of GBX 4.31 and a 52 week high of GBX 19.50. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. The firm has a market capitalization of £53.35 million, a price-to-earnings ratio of 10.06 and a beta of 1.67.

hVIVO (LON:HVO) last posted its quarterly earnings data on Wednesday, April 15th. The company reported GBX (0.87) EPS for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.The firm had revenue of GBX 4,677 million during the quarter. Research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Wall Street Analyst Weigh In

HVO has been the subject of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “hold” rating and issued a GBX 10 price objective on shares of hVIVO in a research note on Wednesday, April 15th. Shore Capital Group reaffirmed a “buy” rating on shares of hVIVO in a research note on Wednesday. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 15.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.